Viracta Therapeutics Inc (VIRX)

Currency in USD
0.0098
+0.0002(+2.08%)
Closed·
Showing Viracta Therapeutics historical data. For real-time data please try another search
Fair Value
Day's Range
0.00800.0110
52 wk Range
0.00800.5800
Key Statistics
Prev. Close
0.0096
Open
0.0107
Day's Range
0.008-0.011
52 wk Range
0.008-0.58
Volume
484.03K
Average Volume (3m)
165.03K
1-Year Change
-96.81%
Book Value / Share
-0.17
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
VIRX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Currently not supported.

Viracta Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Viracta Therapeutics Inc Company Profile

Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. The company’s lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. It’s Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. The company’s product pipeline also includes vecabrutinib, a clinical-stage product candidate; and VRx-510, a preclinical product candidate. The company is headquartered in Cardiff, California.

Viracta Therapeutics Inc SWOT Analysis


Pipeline Pivot
Viracta narrows focus to Nana-val for EBV+ lymphomas, pausing solid tumor program to streamline development and regulatory pathways
Regulatory Clarity
FDA discussions yield potential accelerated approval filing for Nana-val in 2026, offering a clearer path to market for Viracta's lead candidate
Financial Challenges
With $30M cash reserves and a reduced workforce, Viracta faces financial hurdles while aiming to extend runway for key clinical milestones
Market Positioning
Explore Viracta's strategy to dominate the EBV+ lymphoma niche, balancing specialized focus against broader market opportunities
Read full SWOT analysis

Compare VIRX to Peers and Sector

Metrics to compare
VIRX
Peers
Sector
Relationship
P/E Ratio
0.0x−3.1x−0.5x
PEG Ratio
0.000.000.00
Price/Book
−0.1x0.9x2.6x
Price / LTM Sales
-3.8x3.3x
Upside (Analyst Target)
-203.4%40.1%
Fair Value Upside
Unlock0.8%5.1%Unlock

Earnings

Latest Release
Aug 06, 2025
EPS / Forecast
-- / -0.22
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

VIRX Income Statement

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.